X

INDICATIONS

TAZVERIK is indicated for the treatment of: Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. Adult patients with relapsed or refractory…Read more

TAZVERIK is indicated for the treatment of: Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. Adult patients with relapsed or refractory lymphoma who have no satisfactory alternative treatment options.

These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Read less

For U.S. Healthcare Professionals Only

header mobile logo

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

This website is for U.S. audiences only

WELCOME.   
PLEASE   
SELECT AN   
OPTION TO   
GET STARTED.

WELCOME. PLEASE SELECT AN OPTION TO GET STARTED.

I am a:
Interested in:
home slider mobile image

Actor portrayal

CHANGE THE TUNE

CONSIDER TAZVERIK® (TAZEMETOSTAT) FOR YOUR APPROPRIATE ADULT PATIENTS WITH R/R FOLLICULAR LYMPHOMA

TAZVERIK® is indicated for the treatment of:

  • Adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.​

  • Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

ncn logo

Tazemetostat (TAZVERIK®) is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas with a category 2A recommendation as an option for appropriate patients with R/R FL.2

    Explore TAZVERIK efficacy results

    TAZVERIK demonstrated efficacy in relapsed or refractory FL patients studied.1

    CLINICAL TRIAL RESULTS

    View the TAZVERIK safety data

    Learn more about how safety and
    tolerability were evaluated in the trial.

    SAFETY & TOLERABILITY

    Learn about oral dosing & administration

    TAZVERIK is the only FDA-approved oral monotherapy for R/R FL.1,3

    RECOMMENDED DOSE

    Questions about TAZVERIK?

    Ipsen is here to help.
    Request to have a representative
    contact you.

    REQUEST A REP

R/R=relapsed or refractory; FL=follicular lymphoma, EZH2=enhancer of zeste homolog 2.

References: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020. 2. Referenced with permission
from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas V.2.2023. © National Comprehensive
Cancer Network, Inc. 2023. All rights reserved. Accessed February 8, 2023. To view the most recent and complete version of the guideline,
go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any
responsibility for their application or use in any way. 3. U.S. Food & Drug Administration (FDA). FDALabel Database. Accessed March 2,
2022. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/348976.

See how TAZVERIK
was studied in the clinical trial.

STUDY DESIGN